Enhancing patient care and advancing innovation with the only
long-term implantable continuous glucose monitor
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and manufacturing of
long-term, implantable continuous glucose monitor (CGM) systems for
people with diabetes, in partnership with our global commercial
partner, Ascensia Diabetes Care, and St. Louis-based Mercy, a
leading health care system and accountable care organization, today
announced a first-of-its-kind relationship in a diabetes population
management program.
The collaboration marks the first time Senseonics’ Eversense CGM
technology will be used across a health system and the first
implementation of Senseonics’ new Eversense Remote Patient
Monitoring (RPM) solution to drive significant advancement in
diabetes management for patients.
“There are many barriers patients with diabetes struggle with
and glucose monitoring is at the top,” said Dr. Jeff Ciaramita,
President, Mercy specialty service lines. “We believe the launch of
the Eversense Remote Patient Monitoring program will transform
diabetes care for our patients and providers. This program is
designed to enhance our ability to monitor patient health remotely
and support timely interventions that can significantly improve our
patients’ lives and reduce costly, avoidable hospitalizations.”
Mercy has more than a decade of experience with remote patient
monitoring for a variety of conditions. With more than 3 million
patients served annually, it is expected that approximately 30,000
Mercy patients could benefit from a CGM system. Providers at Mercy
plan to begin placing new Eversense devices with patients this
July. In a phased approach, Mercy will roll the program out first
in its St. Louis-area communities followed by the remaining regions
in Mercy’s system in Missouri, Kansas, Arkansas and Oklahoma
throughout 2025.
“We plan to work with our physicians, from the Mercy
proceduralists, who will perform insertions, to the primary care
teams who monitor patients regularly and endocrinologists who
support at-risk patients,” Dr. Ciaramita said. “The integration of
the Eversense CGM+RPM solution is a representation of Mercy’s
ongoing commitment to providing our patients proactive, predictive
and personalized care.”
The goal for the Eversense RPM program is to ensure all patients
who could benefit from Eversense begin treatment over the next 24
to 36 months.
“Mercy is known as an innovative health care leader, so it makes
sense that they are the first health system to work with us towards
providing a comprehensive approach towards better diabetes care,”
said Tim Goodnow, PhD, Senseonics president and chief executive
officer. “Together with Mercy and Ascensia, we are building a
forward-looking approach to provide access for diabetes patients,
from identifying those in need to leveraging the latest continuous
glucose monitoring technology and providing the support patients
need to better self-manage their diabetes. Additionally, we plan to
work with Mercy to provide patient access to our exciting future
products, including the next-gen 365-day product we hope to bring
to market later this year. Together, we are pushing the frontier of
diabetes management.”
Revolutionizing Diabetes Care
Eversense CGM offers a unique approach to diabetes management,
targeted at enabling patients and providers to achieve better
glycemic control and reduce the risk of diabetes-related
complications. With the addition of the new Eversense RPM solution,
patients will receive ongoing coaching and guidance to facilitate
improved outcomes beyond CGM alone. The program is intended to
enhance the quality of life for Mercy patients by making diabetes
management easier and more accurate.
A Strategic Move Towards Cost Reduction and Improved
Outcomes
The implementation of Eversense CGM+RPM across Mercy is a step
forward in enhancing patient care and a strategic move to reduce
health care costs. By improving glucose monitoring and enhancing
patients’ ability to self-manage their diabetes, Mercy aims to
reduce the incidence of emergency room visits and hospitalizations
due to diabetes-related complications, leading to significant cost
savings and better health outcomes.
Commitment to Health Care Innovation
Mercy has been at the forefront of health care innovation, as
evidenced by its inclusion as one of America’s Most Innovative
Companies by Fortune magazine in 2023. The relationship with
Senseonics is a continuation of Mercy’s mission to incorporate
cutting-edge technologies that enhance patient care and operational
efficiencies. This collaboration represents a shared vision with
health care innovation as a cornerstone.
About Mercy
Mercy, one of the 20 largest U.S. health systems and named the
top large system in the U.S. for excellent patient experience by
NRC Health, serves millions annually with nationally recognized
care and one of the nation’s largest and highest performing
Accountable Care Organizations in quality and cost. Mercy is a
highly integrated, multi-state health care system including more
than 50 acute care and specialty (heart, children’s, orthopedic and
rehab) hospitals, convenient and urgent care locations, imaging
centers and pharmacies. Mercy has over 900 physician practice
locations and outpatient facilities, more than 4,500 physicians and
advanced practitioners and 50,000 co-workers serving patients and
families across Arkansas, Kansas, Missouri and Oklahoma. Mercy also
has clinics, outpatient services and outreach ministries in
Arkansas, Louisiana, Mississippi and Texas. In fiscal year 2023
alone, Mercy provided more than half a billion dollars of free care
and other community benefits, including traditional charity care
and unreimbursed Medicaid.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Eversense® is the first and only long-term implantable CGM system
to receive FDA approval.
About Eversense
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels for up to 180
days in persons with diabetes age 18 and older. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration primarily one time
a day after day 21, and when symptoms do not match CGM information
or when taking medications of the tetracycline class. The sensor
insertion and removal procedures are performed by a health care
provider. The Eversense E3 CGM System is a prescription device;
patients should talk to their health care provider to learn more.
For important safety information, see
https://www.ascensiadiabetes.com/eversense/safety-info/.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including statements regarding
launch expectations for Eversense and Eversense RPM programs,
statements regarding growing the awareness, design, adoption,
growth and potential benefits of Eversense and Eversense RPM,
statements regarding potential plans and prospects for
implementation and integration of Eversense RPM, statements
regarding progress and timing of collaboration and adoption with
respect to Eversense and any health system, or its patients and
providers, statements regarding the attributes and value to
patients, patient care and health systems of any such CGM and/or
RPM systems, statements regarding regulatory submissions, potential
market availability, and approaches for the Eversense product, and
other statements containing the words "believe," "expect,"
"intend," "may," "projects," "will," "planned," and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: uncertainties in insurer, regulatory and
administrative processes and decisions, uncertainties inherent in
the development of new technology and/or programs, uncertainties
inherent in finalizing integration and commercial terms with new
partners and other third parties, uncertainties inherent in the
ongoing commercialization of the Eversense product and the
expansion of the Eversense product and a new RPM solution,
uncertainties inherent in Ascensia's performance and other
commercial initiatives, uncertainties relating to the current
economic environment and such other factors as are set forth in the
risk factors detailed in Senseonics' Annual Report on Form 10-K for
the year ended December 31, 2023 and Senseonics' other filings with
the SEC under the heading "Risk Factors." In addition, the
forward-looking statements included in this press release represent
Senseonics' views as of the date hereof. Senseonics anticipates
that subsequent events and developments will cause Senseonics'
views to change. However, while Senseonics may elect to update
these forward-looking statements at some point in the future,
Senseonics specifically disclaims any obligation to do so except as
required by law. These forward-looking statements should not be
relied upon as representing Senseonics' views as of any date
subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513642327/en/
For more information, contact: Mercy Media Relations
Bethany Pope 314-251-4472 Website: mercy.net
Bethany.Pope@Mercy.Net
Senseonics Investor Contact: Philip Taylor Gilmartin
Group 415-937-5406 Investors@senseonics.com
Senseonics (AMEX:SENS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Senseonics (AMEX:SENS)
Gráfica de Acción Histórica
De May 2023 a May 2024
